Biology Reference
In-Depth Information
Table 3
Clinical trials
Average time to drug
Primary end-point
Secondary end-point
Name/year/
references
Number
of pt
EPO, type
and dose
From
onset
Country
From PCI
Measurements
Outcome
Measurements
Outcome
Lipsic 2006 (
21
)
The
Netherlands
20
Darbepoetin
alfa
60,000 IU
NA
0 min
LVEF at 4 m
NS
NA
NA
Liem, 2009 (
22
)
The
Netherlands
51
Epoetin alfa
40,000 IU
8 h from
elevated
tro-
ponin
NA
MI size
(enzymes)
NS
NA
NA
Binbrec, 2009
(
23, 24
)
Dubai
236
Epoetin beta
30,000 IU
6 h
At the time of
thrombolysis
MI size
(enzymes)
NS
Echo at
discharge
NS
EPO/AMI-1,
2010
(
25, 26
)
Japan
36
Epoetin beta
12,000 IU
Within
48 h
Within 24 h
LVEF 4 day
and 6 month
NS
NA
NA
HEBE III 2010
(
27, 28
)
The
Netherlands,
Germany
529
Epoetin alfa
60,000 IU
12-24 h
Within 3 h
LVEF at 6
weeks
NS
MI size
(enzymes)
NS
REVIVAL-3,
2010(
29
)
Germany
138
Epoetin beta
33,300 IU
Within
24 h
0 min (add.
doses at 24
and 48 h)
LVEF at 6
month
NS
Δ
LVEF and MI
NS
EPOC-AMI,
2010(
30
)
Japan
35
Epoetin beta
6,000 IU
Within
24 h
0 min (add.
doses at 24
and 48 h)
MI size 4 days
and 6 month
NS
NA
NA
(continued)
Search WWH ::
Custom Search